A citation-based method for searching scientific literature

Clifford J Bailey, Stefano Del Prato, Cheryl Wei, Daniel Reyner, Gabriela Saraiva. Diabetes Obes Metab 2019
Times Cited: 6







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva. Arch Endocrinol Metab 2018
7
33



Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Yehuda Handelsman, Chantal Mathieu, Stefano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez, Julio Rosenstock. Diabetes Obes Metab 2019
10
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus.
Sanjay Kalra, Nor Azmi Kamaruddin, Jayanti Visvanathan, Ravi Santani. Eur Endocrinol 2019
4
50





Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
366
16

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin Pharmacol Ther 2009
269
16

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Ralph A DeFronzo, Miguel N Hissa, Alan J Garber, Jorge Luiz Gross, Raina Yuyan Duan, Shoba Ravichandran, Roland S Chen. Diabetes Care 2009
325
16

Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data.
Hansoo Kim, Lyle Gurrin, Zanfina Ademi, Danny Liew. Br J Clin Pharmacol 2014
26
16

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
202
16

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. J Diabetes Res 2015
32
16

Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu, Edoardo Mannucci. Diabetes Obes Metab 2018
15
16


Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Nir Barzilai, Hua Guo, Erin M Mahoney, Suzanne Caporossi, Gregory T Golm, Ronald B Langdon, Debora Williams-Herman, Keith D Kaufman, John M Amatruda, Barry J Goldstein,[...]. Curr Med Res Opin 2011
101
16



Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Richard E Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B Huyck, Yanping Qiu, Sheila Sunga, Jeremy Johnson, Steven G Terra, James P Mancuso,[...]. Diabetes Obes Metab 2018
87
16

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.
A S Abdelmoneim, D T Eurich, P E Light, P A Senior, J M Seubert, M J Makowsky, S H Simpson. Diabetes Obes Metab 2015
47
16




The effect of glucagon-like peptide 1 on cardiovascular risk.
Jacob Sivertsen, Jaya Rosenmeier, Jens J Holst, Tina Vilsbøll. Nat Rev Cardiol 2012
110
16

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, Nianping Hu, David N Juurlink, J Michael Paterson,[...]. JAMA Intern Med 2016
53
16

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
16

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
576
16

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
16

DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Wenjia Yang, Xiaoling Cai, Xueyao Han, Linong Ji. Diabetes Metab Res Rev 2016
37
16

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Ildiko Lingvay, Federico Pérez Manghi, Pedro García-Hernández, Paul Norwood, Lucine Lehmann, Mads Jeppe Tarp-Johansen, John B Buse. JAMA 2016
117
16





Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
16

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
16


DPP-4 inhibitors: pharmacological differences and their clinical implications.
Antonio Ceriello, Liberata Sportiello, Concetta Rafaniello, Francesco Rossi. Expert Opin Drug Saf 2014
37
16


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg,[...]. Diabetes Care 2015
101
16

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Petra J W Pouwels, Indra C Pieters-van den Bos, Trynke Hoekstra, Michaela Diamant, Daniël H van Raalte, Djuna L Cahen. Diabetologia 2016
67
16

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
16



Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
Islam Y Elgendy, Ahmed N Mahmoud, Amr F Barakat, Akram Y Elgendy, Marwan Saad, Ahmed Abuzaid, Siddarth A Wayangankar, Anthony A Bavry. Am J Cardiovasc Drugs 2017
29
16

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
16

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
39
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.